Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

Sugen's New Sponsor Is P&U; $650 Mil. Deal Supplants AstraZeneca

  • News

Executive Summary

Pharmacia & Upjohn will be the new big pharma sponsor for oncologic development projects stemming from Sugen's nine-year program in tyrosine kinase and tyrosine phosphatase signal transduction.

You may also be interested in...



Pfizer R&D Reshuffling Deals Out Pharmacia’s Investment In Sugen

Pfizer will cease investment in the biotech company Sugen as part of a reorganization of Pfizer/Pharmacia's combined R&D facilities

Pfizer R&D Reshuffling Deals Out Pharmacia’s Investment In Sugen

Pfizer will cease investment in the biotech company Sugen as part of a reorganization of Pfizer/Pharmacia's combined R&D facilities

Pharmacia Somavert Clears FDA For Acromegaly; Liver Testing Recommended

Labeling for Pharmacia's acromegaly treatment Somavert recommends monthly liver function monitoring for the first six months of treatment

Table

View full table

Tags:
Latest Headlines

Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa

Partisan Politics Returns To US FDA Congressional Oversight

GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows

Pink Sheet Podcast: Leqembi Spending, Woodcock’s Next Act, Pneumococcal Vaccine Development

See All
UsernamePublicRestriction

Register

PS034382

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By